Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. EMJ. 2020;5:29-36.

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Rezvanizadeh V, Golub I, Birudaraju D, Cherukuri L, Hamal S, Dailing C, Flores F, Roy SK, Nelson J, Budoff MJ. Association of inflammatory markers with baseline coronary plaque volumes by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 10:1720.
Miller M, Ballantyne C, Bays H, Granowitz C, Doyle R, Juliano R, Philip S. Icosapent ethyl (eicosapentaenoic acid ethyl ester) reduces potentially atherogenic lipid, lipoprotein, apolipoprotein, and inflammatory parameters in high-risk, statin-treated patients with persistent elevated triglycerides and high-sensitivity C-reactive protein: a post hoc subanalysis of the ANCHOR study [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1392.

In Chronological Order


Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019; epub ahead of print.

Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020; epub ahead of print.

Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT Jr, Juliano RA, Philip S. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study). Am J Cardiol.2019; epub ahead of print.

Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statinBiomed Pharmacother. 2018;103:1231-7.

Borow KM, Mason RP, Vijayaraghavan K. Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review. Cardiorenal Med. 2018;8:18-30.

Mason RP, Jacob RF, Shrivastava S, Sherratt SC, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131-3140.

Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68:33-40.
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
440 ROUTE 22
+1 908 719 3012

Amarin Corporation